Albany, NY -- (SBWIRE) -- 12/19/2013 -- Traditional Wound Management Market to 2019 - Cost Sensitivity Spurs Adoption in Emerging Markets, as Uptake of Advanced Wound Management Products Limits Growth in Developed Economies

Traditional Wound Management Market to 2019 looks at the market, key market players, and market dynamics for the global traditional wound management market. It provides a synopsis of the various factors influencing the market and its segments – bandages, gauzes and sponges. The report also gives company descriptions, lists the key marketed products for major market players and details of important M&A deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/traditional-wound-management-market-to-2019-cost-sensitivity-spurs-adoption-in-emerging-markets-as-uptake-of-advanced-wound-management-products-limits-growth-in-developed-economies

Scope

Key geographies: the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia and Brazil
Information on market size for the three traditional wound management market segments: bandages, gauzes and sponges
Annualized market-revenue data forecast to 2019, and company share data for 2012

Reasons to Buy

Develop business strategies by understanding the dynamics and developments driving the global traditional wound management market
Design and enhance your product development, marketing, and sales strategies
Develop market-entry and market-expansion strategies
Identify the key players best positioned to take advantage of the emerging market opportunities
Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return
Identify, understand and capitalize on the next big thing in the traditional wound management market landscape
Make more informed business decisions based upon insightful analysis of the global traditional wound management market and the factors shaping it.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/180754

Table of Contents

1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7

2 Executive Summary 8
2.1 Traditional Wound Management Market is Forecast to Reach $1.9 Billion by 2019 8
2.2 Presence of Low-Cost Affordable Models in Developing Countries is Driving Adoption 9
2.3 Preference for Advanced Wound Management Modalities in Developed Economies to Deter Market Growth 10
2.4 Need for Minimal Technical Knowledge of Traditional Wound Management Products to Drive Growth 12

3 Introduction 13
3.1 GBI Research Guidance 13

4 Global Traditional Wound Management Market, Device Overview 14
4.1 Bandages 14
4.2 Gauzes 14
4.3 Sponges 14

5 Global Traditional Wound Management Market, Market Characterization 15
5.1 Global Traditional Wound Management Market, Revenue, 2005–2012 15
5.2 Global Traditional Wound Management Market, Revenue, 2012–2019 16
5.3 Global Traditional Wound Management Market, Key Company Shares, 2012 18
5.4 Global Traditional Wound Management, Market Dynamics 20
5.4.1 Market Drivers 20
5.4.1.1 Need for Minimal Technical Knowledge of Traditional Wound Management Products to Drive Growth 20
5.4.1.2 Traditional Wound Management Remains the Primary Mode of Treatment in Developing Countries 21
5.4.1.3 Low-Cost Models of Traditional Wound Management Products 21
5.4.2 Market Restraints 22
5.4.2.1 Increasing Preference for Advanced Wound Management in Developed Economies 22
5.4.2.2 Increasing Awareness of the Importance of Advanced Wound Management 23

6 Global Traditional Wound Management Market, Country-Specific Revenue (2005–2019) 25
6.1 Traditional Wound Management Market: Country-Specific Analysis 25
6.2 Historic and Forecast Revenue, by Country 26
6.2.1 Traditional Wound Management Market, US, Revenue, 2005–2012 26
6.2.2 Traditional Wound Management Market, US, Revenue, 2012–2019 28
6.2.3 Traditional Wound Management Market, Japan, Revenue, 2005–2012 29
6.2.4 Traditional Wound Management Market, Japan, Revenue, 2012–2019 30
6.2.5 Traditional Wound Management Market, Germany, Revenue, 2005–2012 32
6.2.6 Traditional Wound Management Market, Germany, Revenue, 2012–2019 33
6.2.7 Traditional Wound Management Market, Brazil, Revenue, 2005–2012 35
6.2.8 Traditional Wound Management Market, Brazil, Revenue, 2012–2019 36
6.2.9 Traditional Wound Management Market, France, Revenue, 2005–2012 37
6.2.10 Traditional Wound Management Market, France, Revenue, 2012–2019 39
6.2.11 Traditional Wound Management Market, China, Revenue, 2005–2012 40
6.2.12 Traditional Wound Management Market, China, Revenue, 2012–2019 41
6.2.13 Traditional Wound Management Market, UK, Revenue, 2005–2012 43
6.2.14 Traditional Wound Management Market, UK, Revenue, 2012–2019 44
6.2.15 Traditional Wound Management Market, Italy, Revenue, 2005–2012 45
6.2.16 Traditional Wound Management Market, Italy, Revenue, 2012–2019 46
6.2.17 Traditional Wound Management Market, Canada, Revenue, 2005–2012 48
6.2.18 Traditional Wound Management Market, Canada, Revenue, 2012–2019 49
6.2.19 Traditional Wound Management Market, Spain, Revenue, 2005–2012 50
6.2.20 Traditional Wound Management Market, Spain, Revenue, 2012–2019 52
6.2.21 Traditional Wound Management Market, Australia, Revenue, 2005–2012 53
6.2.22 Traditional Wound Management Market, Australia, Revenue, 2012–2019 54
6.2.23 Traditional Wound Management Market, India, Revenue, 2005–2012 56
6.2.24 Traditional Wound Management Market, India, Revenue, 2012–2019 57

7 Global Traditional Wound Management Market, Reimbursement Systems 59
7.1 US 60
7.2 Japan 60
7.3 Germany 60
7.4 UK 61
7.5 France 61
7.6 Italy 61
7.7 Australia 61
7.8 Spain 62

8 Global Traditional Wound Management Market, Distribution Systems 63

9 Global Traditional Wound Management Market, Company Profiles 64
9.1 Paul Hartmann AG 64
9.1.1 Business Overview 64
9.2 Johnson & Johnson 64
9.2.1 Business Overview 64
9.3 Covidien plc 65
9.3.1 Business Overview 65
9.4 B. Braun Melsungen AG 65
9.4.1 Business Overview 65
9.5 Cremer SA 66
9.5.1 Business Overview 66
9.6 Mölnlycke Health Care AB 66
9.6.1 Business Overview 66
9.7 Synergy Health plc 67
9.7.1 Business Overview 67
9.8 Hollister Incorporated 67
9.8.1 Business Overview 67

10 Global Traditional Wound Management Market, Consolidation Landscape 68

To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/180754

11 Appendix 70
11.1 Definitions 70
11.1.1 Bandages 70
11.1.2 Gauzes 70
11.1.3 Sponges 70
11.2 Acronyms 70
11.3 Sources 70
11.4 Research Methodology 72
11.4.1 Secondary Research 72
11.4.2 Primary Research 72
11.4.3 Models 73
11.4.4 Forecasts 73
11.4.5 Expert Panels 73
11.5 Contact Us 74
11.6 Disclaimer 74
Table 1: Traditional Wound Management Market, Global, Revenue ($m), 2005–2012 16
Table 2: Traditional Wound Management Market, Global, Revenue Forecast ($m), 2012–2019 17
Table 3: Traditional Wound Management Market, Global, Key Company Revenue ($m), 2012 19
Table 4: Summary of Foam Dressings Clinical Trial 23
Table 5: Traditional Wound Management Market, Global, Matched Samples of Patients, 2005 and 2006 24
Table 6: Traditional Wound Management Market, Global, Cross-Country Analysis, CAGR (%), 2005–2019 26
Table 7: Traditional Wound Management Market, US, Revenue ($m), 2005–2012 27
Table 8: Traditional Wound Management Market, US, Revenue Forecast ($m), 2012–2019 29
Table 9: Traditional Wound Management Market, Japan, Revenue ($m), 2005–2012 30
Table 10: Traditional Wound Management Market, Japan, Revenue Forecast ($m), 2012–2019 31
Table 11: Traditional Wound Management Market, Germany, Revenue ($m), 2005–2012 33
Table 12: Traditional Wound Management Market, Germany, Revenue Forecast ($m), 2012–2019 34
Table 13: Traditional Wound Management Market, Brazil, Revenue ($m), 2005–2012 35
Table 14: Traditional Wound Management Market, Brazil, Revenue Forecast ($m), 2012–2019 36
Table 15: Traditional Wound Management Market, France, Revenue ($m), 2005–2012 38
Table 16: Traditional Wound Management Market, France, Revenue Forecast ($m), 2012–2019 39
Table 17: Traditional Wound Management Market, China, Revenue ($m), 2005–2012 41
Table 18: Traditional Wound Management Market, China, Revenue Forecast ($m), 2012–2019 42
Table 19: Traditional Wound Management Market, UK, Revenue ($m), 2005–2012 43
Table 20: Traditional Wound Management Market, UK, Revenue Forecast ($m), 2012–2019 45
Table 21: Traditional Wound Management Market, Italy, Revenue ($m), 2005–2012 46
Table 22: Traditional Wound Management Market, Italy, Revenue Forecast ($m), 2012–2019 47
Table 23: Traditional Wound Management Market, Canada, Revenue ($m), 2005–2012 48
Table 24: Traditional Wound Management Market, Canada, Revenue Forecast ($m), 2012–2019 50
Table 25: Traditional Wound Management Market, Spain, Revenue ($m), 2005–2012 51
Table 26: Traditional Wound Management Market, Spain, Revenue Forecast ($m), 2012–2019 53
Table 27: Traditional Wound Management Market, Australia, Revenue ($m), 2005–2012 54
Table 28: Traditional Wound Management Market, Australia, Revenue Forecast ($m), 2012–2019 55
Table 29: Traditional Wound Management Market, India, Revenue ($m), 2005–2012 57
Table 30: Traditional Wound Management Market, India, Revenue Forecast ($m), 2012–2019 58
Table 31: Traditional Wound Management Market, Global, Consolidation Landscape, 2008–2013 68
Figure 1: Traditional Wound Management Market, Global, Revenue Forecast ($bn), 2012–2019 8
Figure 2: Traditional Wound Management Market, Global, Weighted Average Selling Price ($), CAGR (2012–2019) (%) 9
Figure 3: Wound Dressings Market, Global, Revenue Forecast ($bn), 2012–2019 10
Figure 3: Traditional Wound Management Market, Global, Revenue ($m), 2005–2012 15
Figure 4: Traditional Wound Management Market, Global, Revenue Forecast ($m), 2012–2019 17
Figure 5: Traditional Wound Management Market, Global, Key Company Shares (%), 2012 18
Figure 6: Traditional Wound Management Market, Market Dynamics 20
Figure 7: Traditional Wound Management Market, Geographical Market Share (%), 2012–2019 22
Figure 8: Traditional Wound Management Market, Global, Country-Specific Analysis, CAGR (%), 2005–2019 25
Figure 9: Traditional Wound Management Market, US, Revenue ($m), 2005–2012 27
Figure 10: Traditional Wound Management Market, US, Revenue Forecast ($m), 2012–2019 28
Figure 11: Traditional Wound Management Market, Japan, Revenue ($m), 2005–2012 29
Figure 12: Traditional Wound Management Market, Japan, Revenue Forecast ($m), 2012–2019 31
Figure 13: Traditional Wound Management Market, Germany, Revenue ($m), 2005–2012 32

Latest Reports:

Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019: http://www.marketresearchreports.biz/analysis-details/type-2-diabetes-therapeutics-market-to-2019-a-shifting-treatment-algorithm-and-intensified-competition-expected-to-drive-growth-by-2019

Pharmaceuticals industry, “Type 2 Diabetes Therapeutics Market to 2019 A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019”. There is currently a large number of blood glucose-lowering drugs in the crowded type 2 diabetes market indicated for the treatment of chronically high blood glucose. The market is led by Lantus, which achieved global sales amounting to $6.4 billion in 2012. Over the forecast period from 2012 to 2019, the safer, more efficacious newer classes of drug (GLP-1 agonists, DPP-4 Inhibitors and SGLT-2 inhibitors) are expected to capture substantial market shares, largely replacing older classes such as sulfonylureas and thiazolidinediones. Additionally, a variety of novel drugs belonging to these newer classes are due to enter the market, and are expected to offer a moderate improvement in terms of efficacy and safety. The price of these new therapies is expected to be high, but this is unlikely to hinder their uptake. As a result, as well as an overall increase in the prevalent population, GBI Research believes that the value of the global market has the potential to grow to reach $38.8 billion by 2019.

Scope

A brief introduction to type 2 diabetes, including the symptoms, pathogenesis, risk factors and diagnosis
In-depth analysis of major glucose-lowering drugs for type 2 diabetes, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.
Comprehensive review of the pipeline for type 2 diabetes therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action
Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain
Discussion of the drivers and barriers for market growth

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/177234

Reasons to buy

Understand the many different types of type 2 diabetes therapies on the market, from the older, established classes of treatment to newer, moderately superior types of drug, and their positions in the treatment algorithm
Understand the strengths and weaknesses of each product
Understand the scope of the pipeline, including which molecule types and mechanisms of action are prominent
Observe trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for type 2 diabetes therapeutics
Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the type 2 diabetes therapeutics market.

Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth: http://www.marketresearchreports.biz/analysis-details/monoclonal-antibodies-market-in-breast-cancer-to-2019-strong-uptake-of-novel-her-2-targeted-therapies-to-drive-robust-growth

Pharmaceutical report “Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth”. The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2) protein. Four are aimed at improving overall survival in the metastatic setting, and two of these have also received further approvals in the early setting in order to improve long-term remission rates.

The market is currently led by the HER-2 inhibitor Herceptin, which achieved global sales amounting to $6.2 billion in 2012. Over the forecast period from 2012 to 2019, the two novel HER-2 inhibitors, Kadcyla and Perjeta, are expected to achieve strong market penetration due to their appreciable incremental efficacy benefits. Additionally, the market conditions are currently favorable towards mAbs, with a low rate of price depreciation following patent expiry and a high rate of inflation for specialty pharmaceuticals in the US. As a result of this, and despite the empty Phase III pipeline, GBI Research believes that the global market across the leading eight countries have the potential to grow to a value of $10.6 billion by 2019.

Scope

An introduction to the treatments available for breast cancer, treatment algorithms and the contexts in which mAbs are clinically relevant to this type of cancer.
In-depth analysis of the five mAbs approved for breast cancer, with analysis of their safety, efficacy, treatment patterns and strengths and weaknesses. This includes a heat map comparing the drugs in terms of clinical trial results.
A comprehensive review of the pipeline for breast cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline for mAbs is analyzed on the basis of phase distribution, program type and molecular target, as is the entire pipeline for all molecule types.
Detailed analysis of pipeline drug clinical trials by trial size, trial duration and program failure rate for each molecule type and mechanism of action. Additionally, a detailed analysis of clinical trial endpoints is provided, detailing their importance in this disease area and their commercial relevance to currently marketed products.
Multi-scenario forecast data for the market is provided to 2019, which takes into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain.
Discussion of the drivers and barriers for market growth
Complete analysis of licensing and co-development deals in this market, by year, value, molecule type, Phase and mechanism of action. Additionally, the international network of licensing deals in breast cancer is mapped out by geography.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/178527

Reasons to Buy

Understand the different indications for breast cancer, from early-stage to the metastatic disease
Grasp the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent, and the context of mAbs in the pipeline
Pinpoint the trends in clinical trial duration and size amongst clinical Phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for breast cancer therapeutics. Determine the risk associated with the development of mAbs compared to other molecule types.
Observe the shift in clinical trial endpoints by clinical Phase, and use this data to potentially influence any future developmental programs. Understand the importance of selecting the correct endpoints in the study of drugs for this disease.
Assess the potential clinical and commercial impact of recently-approved molecules on the breast cancer market and determine the potential revenues associated with the launch of a novel product, in addition to the level of competitiveness in the market.

About MarketResearchReports.Biz
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Blog: http://mrrfocuseconomics.blogspot.com/